BEGIN:VCALENDAR VERSION:2.0 X-WR-CALNAME;VALUE=TEXT:8th Neurodegenerative Conditions Research & Development Conference PRODID:-//Harvard events data//EN BEGIN:VEVENT UID:event_222546_0 SUMMARY:8th Neurodegenerative Conditions Research & Development Conference DESCRIPTION:

Register by July 18, 2014 and receive the 20% early registration discount.
Or sign up 3 people for the price of 2 using discount code rcdvb.

Submit an abstract by August 18, 2014 and reserve a poster board at the conference to showcase your research. Top abstracts will be selected for an oral presentation. Selected presentations will be based on quality of abstract and availability.

Selected topics:

  1. Using Known Risk Factors in Alzheimer's Disease for Drug Discovery Strategy and Patient Stratification
    Marcie Glicksman, Co-Director of the Laboratory for Drug Discovery at Harvard NeuroDiscovery Center
    Learn how the Laboratory for Drug Discovery has been working with two identified risk factors and using patient's cells for profiling and high throughput screening.

  2. BACE1 Inhibition as a Therapeutic Strategy for Alzheimer's Disease
    Robert Vassar, Professor of Cell and Molecular Biology at the Feinberg School of Medicine, Northwestern University
    Dr. Vassar will discuss the role of the beta-secretase enzyme BACE1 in AD pathogenesis, why BACE1 is a prime therapeutic target for AD, and the potential strengths and weaknesses of BACE1 inhibition as a therapeutic strategy for AD.

  3. Targeting Serotonergic Receptors to Treat L-DOPA-Induced Dyskinesia in Parkinson's Disease
    Mark Varney, Chief Executive Officer of Neurolixis
    Learn about dyskinesia in PD patients and about the role of the 5-HT1A receptors in PD. Gain an understanding to why agonist selectivity and efficacy are critical to testing a hypothesis.

  4. Reshaping the Pathway for AD Therapeutics Development with Biomarkers and Novel Clinical Readouts
    Johan Luthman, Vice President of Neuroscience Clinical Development at Eisai Pharmaceuticals
    Dr. Luthman's presentation will show different types of biomarkers and their diagnostic purposes, efforts to introduce improved clinical outcome measures for early stage AD trials, and understand the process of biomarker and clinical outcome measure qualification and regulatory approval.

Muscarinic Acetylcholine Receptor Subtype 1 Positive Allosteric Modulators for the Treatment of Schizophrenia
Jerri Rook, Instructor, Vanderbilt Center for Neuroscience Drug Discovery
A new approach to discovery of novel highly selective activators of individual muscarinic acetylcholine receptors (mAChR) subtypes and identifying that subtype specific mAChR positive allosteric modulators (PAMs) may provide a novel approach for treatment of multiple CNS disorders.

LOCATION:Sheraton Fisherman's Wharf, San Francisco, CA STATUS:CONFIRMED DTSTART:20140918T120000Z DTEND:20140919T220000Z END:VEVENT END:VCALENDAR